Table 3 CMR findings in the 70 patients that had imaging performed at both baseline and at a median follow-up of 11 months.
Normoglycemia (n = 44) | Dysglycemia (n = 9) | DM (n = 17) | ANOVA P- value | |
|---|---|---|---|---|
LVEDV (ml) | ||||
Baseline | 178 (37) | 159 (28) | 179 (24) | |
Follow-up | 177 (35) | 161 (40) | 183 (36) | 0.31 |
P-value baseline vs. follow-up | NS | NS | NS | |
LVESV (ml) | ||||
Baseline | 95 (26) | 89 (23) | 99 (23) | |
Follow-up | 85 (27) | 81 (30) | 94 (29) | 0.41 |
P-value baseline vs. follow-up | <0.001 | NS | NS | |
Ejection fraction (%) | ||||
Baseline | 47 (6) | 44 (7) | 45 (9) | |
Follow-up | 53 (8) | 50 (7) | 49 (7) | 0.26 |
P-value baseline vs. follow-up | <0.001 | <0.05 | <0.05 | |
LV mass (g) | ||||
Baseline | 117 (29) | 115 (21) | 113 (18) | |
Follow-up | 99 (23) | 95 (20) | 102 (19) | 0.74 |
P-value baseline vs. follow-up | <0.001 | <0.001 | <0.001 | |
%LV-scar | ||||
Baseline | 15 (9) | 23 (11) | 25 (14) | |
Follow-up | 12 (8) | 18 (9) | 19 (10) | 0.02 |
P-value baseline vs. follow-up | <0.001 | <0.05 | <0.05 |